Financial Shenanigans

Financial Shenanigans

Figures converted from euros at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.

1. The Forensic Verdict

Safran prints a Forensic Risk Score of 32 / 100 — Watch. The clean tests dominate: an unqualified opinion from the dual French statutory auditors, no restatements, no AMF or SEC enforcement, separated Chair/CEO, an activist (TCI) and the French State as independent checks on the board, and CEO variable pay tied to working capital so that inflating receivables hurts the bonus. The two real concerns are both balance-sheet flow signals: FY2025 trade receivables grew 35.5% while revenue grew 12.5% (a +23pp gap), and days-payable-outstanding stretched by +30 days to 256, supplying roughly $1.2B of non-recurring tailwind to cash conversion. The one data point that would move the grade meaningfully is the FY2026 H1 update on receivables and contract-asset balances — if the gap closes as state-customer payments arrive, this is timing; if it widens, the bull-case 75% cash conversion ambition is exposed.

Shenanigans scorecard — all 13 categories

2. Breeding Ground

Safran's breeding-ground risk is below average for a French large-cap industrial. The governance structure has multiple credible counterweights to the executive team: a separated chair (Ross McInnes since April 2015), an activist holder (TCI at 8.1% of capital, 9.6% of votes), and a French-State seat (Bpifrance/APE) sitting on the Audit & Risk Committee. The board is 58% independent, attendance averaged 98% in 2025, and the dual French statutory-auditor regime is in place. Crucially, CEO Olivier Andriès' 2025 variable pay reads like a forensic countermeasure: 60% weight on recurring operating income, 25% on free cash flow, 10% on inventories, and 5% on unpaid receivables. Inflating receivables to flatter revenue would mechanically dock the CEO's bonus.

The one yellow that matters is expectation pressure. Safran has met or exceeded every Capital Markets Day cycle since 2015, the FY2025 result beat the initial outlook on every metric, and management raised the 2028 free cash flow ambition mid-cycle from $17.6-20.0B to ~$24.7B. That track record builds management credibility, but it also raises the bar for the kind of timing-driven flatteries that show up most clearly on the balance sheet — which is where most of the yellow flags below live.

3. Earnings Quality

The IFRS income statement is dominated by below-operating mark-to-market on the USD-hedging derivative book. The chart below shows the gap clearly: IFRS net income swings from -$2,623M (FY22) to -$693M (FY24) to +$8,433M (FY25) while operating income trends smoothly upward. Recurring operating income — Safran's adjusted metric — is the cleaner read on underlying earnings, and it has compounded at roughly 30% from FY21 to FY25.

Interpretation. The net income line is, for forensic purposes, noise. The operating-income line — even before adjusted reconciliations — is what investors should anchor to. The $4.7B positive gap between IFRS pretax ($12,066M) and operating income ($4,826M) in FY2025 is almost entirely non-cash gains on FX-derivative MTM, mirrored by a $5.1B negative gap in FY2024 that absorbed the inverse MTM hit. The hedging program itself is real and substantial (~$48B notional, hedge rate 1.12), but its IFRS accounting treatment is what creates the headline volatility, not the operating business.

Revenue quality — the receivables divergence

This is the single most material forensic signal in the file. Receivables grew $6,051M in FY2025 while revenue grew $7,853M — receivables expanded by more than three-quarters of the year's revenue increase. DSO climbed from 137 to 151 days (+14 days). Management attribution in the FY2026 outlook is explicit: "subject to payment schedule of certain advance payments and the rhythm of payments by State customers" — referring primarily to Rafale and defense receivables that swing on French and export government cash. The benign read is timing on Rafale orders that booked late in 2025; the malign read is that revenue was pulled into FY25 to hit the 14.7% growth headline. The H1 2026 receivables print will tell us which it is.

Non-cash income, impairments, and the "one-off" line

The FY2025 $497M impairment charge (likely Aircraft Interiors related — the segment booked a $199M operating loss) is the largest single one-off in years and is excluded from the adjusted ROCI margin walk that drove the 150bps margin expansion narrative. That is defensible accounting treatment, but the pattern of impairments and "infrequent material non-operational items" reappearing year after year deserves the standard skeptical eye. Including the FY2025 impairment, the adjusted operating margin would have been 15.1% — flat year-over-year, not up 150bps. Both numbers are disclosed; the headline is the optimistic one.

4. Cash Flow Quality

Operating cash flow looks strong ($6,722M FY25, +21% YoY), but a meaningful slice is non-recurring working-capital benefit. The chart below decomposes CFO into the cash earnings engine versus working-capital contribution.

The headline cash conversion has held up across the cycle. FCF after acquisitions, however, fell $32M in FY2025 to $3,443M because of the $1,825M outflow for Collins flight-controls/actuation and other smaller deals. Acquisitive growth absorbs roughly 30-50% of free cash flow in active deal years (FY18 absorbed it entirely with Zodiac), so the 3-year cumulative FCF-after-M&A / NI ratio of 0.94 is the more honest cash-quality picture than the 1.17 ratio without M&A.

Working capital — where the FY2025 cash beat really came from

DSO of 151 days and DPO of 256 days are large in absolute terms but consistent with aerospace-OEM payment cycles. The forensic flag is the direction in FY2025: DSO up 14 days, DPO up 30 days, DIO flat. The DPO stretch alone is worth roughly $1.2B of cash flow that would have to reverse if Safran returns to FY2024 supplier-payment timing. Combined with the receivables surge, the FY25 working-capital print is a cocktail of state-customer timing (receivables drag) offset by extended supplier credit (payables tailwind). The headline +$1,257M WC contribution disclosed by management is a net number — it understates how much of the cash came from supplier-finance dynamics.

5. Metric Hygiene

Safran's reporting framework is transparent and reconciled, but designed to put recurring operating income front and centre. Four metrics matter.

The IFRS↔Adjusted bridge tells the real story:

• FY2024: adjusted profit $3,187M, IFRS loss $(693)M. The $3.9B gap is FX-derivative MTM losses excluded from adjusted.
• FY2025: adjusted profit $3,729M, IFRS profit $8,433M. The -$4.7B gap is FX-derivative MTM gains excluded from adjusted.

Adjusted profit growth in FY2025 was only +3.5% ($3,187M → $3,729M, in EUR terms +3.5%), versus the +26% recurring ROCI growth headline. Investors anchoring to the ROCI headline can over-estimate the underlying earnings dynamic. Both numbers are disclosed; the editorial choice of which to lead with is management's, and it leads with the larger growth number.

6. What to Underwrite Next

Five concrete things to track. Order matters: the first is decision-relevant inside two quarters; the rest are next-annual-report material.

1. H1-2026 receivables and contract assets. If FY25's $6.1B receivables build was Rafale-/state-timing, H1-26 should see a partial reversal ($1-2B unwind) and the FY26 H1 DSO should fall back below 145 days. If receivables grow another 20%+ on similar revenue growth, the FY25 14.7% revenue print includes pulled-forward bookings and the bull-case 75% cash conversion is overstated.

2. The factoring / supplier-finance note in the FY2025 URD financial statements. This is the single most useful disclosure to read at the note level. The $1.26B WC tailwind alongside +30-day DPO stretch implies either reverse-factoring or extended supplier terms that won't repeat. The note quantifies the program; the summary does not.

3. FY2026 H1 hedge book mark. The $4.7B IFRS gain in FY25 reflects a softer USD. If the EUR/USD spot reverses toward 1.05-1.10, expect a comparable swing in the other direction — pre-empt the headline shock with the adjusted profit number ($3.73B FY25).

4. Cumulative impairment / "non-recurring" item run-rate. Track the rolling 3-year sum of items excluded from adjusted ROCI. If it stays above 1.5% of revenue (FY25 print: 1.5%), the adjusted margin walk is materially flattered relative to reality.

5. Adjusted vs IFRS EPS divergence. Adjusted EPS $8.93 (FY25) vs IFRS $20.17. Use the $8.93 number for any valuation work. The $20.17 figure should never anchor a multiple.

What would downgrade the forensic grade. A second consecutive year of receivables-growth > 2x revenue growth without explicit state-customer timing being closed out; an undisclosed reverse-factoring program of more than $1.2B; a change in the definition of "recurring" or "adjusted" without prior notice; or a switch in dual statutory auditor without a clear succession explanation.

What would upgrade it. A clean reversal of FY25 receivables in H1-26, a quantified supplier-finance note that confirms the program is modest (under $600M), and continued WC contribution that comes from pricing/aftermarket rather than payable stretch.

Bottom line

This is not a thesis-breaking accounting story. The forensic risk is best characterized as a position-sizing limiter, not a haircut — investors should size Safran on adjusted earnings ($3.73B FY25) and on steady-state free cash flow excluding the $1.26B WC tailwind (~$3.3-3.5B), not on the IFRS $8.4B net income or the $4.6B headline FCF. Doing so removes most of the optical strength from the FY2025 result without changing the underlying conclusion: this is a well-governed aerospace OEM with structural aftermarket tailwinds, audited cleanly, with a credible management team. The forensic flags here would be footnotes in a less expensive stock; at current valuation, they are reasons to wait for the H1-2026 print before pressing position size.